Skip to content
CompoundSci
All peptides
Research vial labelled BPC-157, a Healing and tissue peptide studied in preclinical and clinical literature

BPC-157

Body Protection Compound-157

A large rodent literature on tendon, ligament, muscle and gut healing, mostly from a small number of research groups in Croatia.

Almost all published work is animal-model. Human data is thin, read the limitations.

General profile

Class
Healing and tissue
Evidence
Mixed or moderate evidence
Studied dose range
250–500 mcg (rodent-scaled literature)
Frequency in protocols
1–2× daily in study protocols
Route
Subcutaneous
Half life
~4 hours
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated once reconstituted, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Daily, often split morning and evening in study protocols

Short plasma half-life of roughly 4 hours, so protocols split the daily amount rather than front-loading it. Timing relative to food is not a factor.

Reported cycle: 4 weeks on, 2 weeks off

Injury repair protocols in the animal literature run in short bursts tied to a healing window, not indefinitely. Four to six weeks covers most soft tissue timelines.

Watch for: Injection site irritation, and any new lump, mole change or unexplained pain. Angiogenesis is the whole mechanism, which is exactly why anyone with a cancer history should not be running it.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopBody level hard stop

    BPC-157 + The window right after cardiac surgery

    Not alongside an active cardiac recovery regimen

    Bleeding risk and the cardiac drug regimen come first. Pro-angiogenic and vasodilatory compounds can clash with that care. Physician territory, not a timing problem.

  • Hard stopBody level hard stop

    BPC-157 + Active cancer, pregnancy or heavy immunosuppression

    Absolute stop with an active cancer history

    Angiogenesis is the whole mechanism people are chasing here, and it acts everywhere in the body, not only in the tendon you care about. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference.

  • Hard stopTiming

    BPC-157 + Wolverine (BPC-157 + TB-500)

    Duplicate ingredient

    The Wolverine blend already contains BPC-157. Adding it separately double doses one half of the blend while leaving the other half unchanged.

  • Separate syringesSame day fine, same syringe not

    BPC-157 + Melanotan II

    Keep Melanotan II alone in the barrel

    Melanotan II stays on its own even on a shared protocol day, and it reliably causes nausea, flushing and blood pressure changes in the first hours. If you introduce it next to anything else you cannot attribute a reaction.

  • Separate syringesSame day fine, same syringe not

    BPC-157 + TB-500

    Valid protocol pair, separate syringes by default

    Complementary jobs, local repair signalling versus cell motility and systemic repair logistics. Co-draw stability data is thin, so the default is two syringes on the same day.

  • Separate syringesSame day fine, same syringe not

    BPC-157 + Tesamorelin + Ipamorelin

    That GH pair can share a barrel, BPC-157 stays out

    Tesamorelin and ipamorelin sit in the same GH class and are co-drawn in practice. Adding a healing peptide to that barrel is a cross-family mix with no stability file.

  • Pick oneRedundant, pick one

    BPC-157 + Wolverine (BPC-157 + TB-500)

    Same target hit twice

    Wolverine already contains BPC-157.

  • Pick oneTiming

    BPC-157 + TB-500

    Commonly paired in the literature

    These two are studied together in repair models with no reported interaction. Still give them separate injection sites so any local reaction is traceable to one compound.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how BPC-157 fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed, published human efficacy trial. Nothing is approved for human use anywhere.

Open questions: Dose translation from rodents is guesswork, and long-term angiogenic signalling has never been studied in people.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature